Company Overview
About Mirador Therapeutics
Mirador Therapeutics is a precision immunology company with a genetics-first platform (Mirador360) that uses human genetic data to identify the most biologically validated targets and patient subpopulations for inflammatory and fibrotic diseases. The company closed a $250 million Series B in January 2026, bringing total funding above $650 million, with an ambitious pipeline targeting Crohn's disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis (IPF). Ten or more clinical readouts are expected by end of 2027.
Business Model & Competitive Advantage
Mirador's genetics-first approach is both a scientific and commercial differentiator: human genetic studies identify which biological pathways actually cause disease in humans, rather than relying on animal models that frequently fail to translate. This validation reduces clinical failure risk — the primary driver of biopharma R&D cost — by entering the clinic with the strongest possible biological rationale for each target.
Competitive Landscape 2025–2026
The extraordinary capital accumulation ($650M+) for a company still in clinical development reflects investor conviction that Mirador has the platform and expertise to become a generational immunology company. Immunology is one of the highest-value therapeutic categories: existing approved drugs (Humira, Dupixent, Skyrizi) generate $15-30 billion in annual revenue, and validated next-generation approaches to these diseases command premium valuations.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
Mirador Therapeutics is an established challenger with significant market presence and competitive offerings in BioTech.
Growth Stage
Mirador Therapeutics has achieved $250M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Mirador Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Mirador Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Mirador Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Mirador Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →